We are live on ! Find out more
STML

Stemline Therapeutics, Inc.
STML

Delisted

STML was delisted on the 9th of June, 2020.

Back to rankings

56 hedge funds and large institutions have $184M invested in Stemline Therapeutics, Inc. in 2013 Q2 according to their latest regulatory filings, with 56 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
56
Holders Change
+56
Holders Change %
–
% of All Funds
1.83%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
56
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$35.4M +$23.6M +1,482,956 New
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$22.2M +$14.8M +930,200 New
BBA
3
Baker Bros. Advisors
New York
$21.5M +$14.3M +900,000 New
JRJ
4
Jeffrey R. Jay
$14.2M +$9.48M +595,493 New
PA
5
Perceptive Advisors
New York
$14.1M +$9.42M +591,650 New
VAM
6
Visium Asset Management
New York
$7.15M +$4.78M +300,000 New
JHIU
7
Janus Henderson Investors US
Colorado
$7.07M +$4.73M +296,693 New
Franklin Resources
8
Franklin Resources
California
$6.28M +$4.19M +263,200 New
BFA
9
BlackRock Fund Advisors
California
$5.46M +$3.65M +229,093 New
Neuberger Berman Group
10
Neuberger Berman Group
New York
$5.43M +$3.63M +227,759 New
QF
11
QVT Financial
New York
$5.25M +$3.5M +220,000 New
JP Morgan Chase
12
JP Morgan Chase
New York
$4.87M +$3.25M +204,145 New
SCA
13
SAC Capital Advisors
Connecticut
$3.96M +$2.64M +165,923 New
Vanguard Group
14
Vanguard Group
Pennsylvania
$3.71M +$2.48M +155,493 New
FCM
15
Farallon Capital Management
California
$3.22M +$2.15M +135,000 New
SCM
16
Sigma Capital Management
Connecticut
$2.62M +$1.75M +110,000 New
State Street
17
State Street
Massachusetts
$2.47M +$1.65M +103,752 New
BIT
18
BlackRock Institutional Trust
California
$2.37M +$1.58M +99,299 New
EI
19
EAM Investors
California
$2.15M +$1.44M +90,119 New
D.E. Shaw & Co
20
D.E. Shaw & Co
New York
$1.84M +$1.23M +77,178 New
VM
21
VHCP Management
New York
$1.19M +$796K +50,000 New
TCIM
22
TIAA CREF Investment Management
New York
$1.14M +$761K +47,803 New
Goldman Sachs
23
Goldman Sachs
New York
$1.09M +$730K +45,827 New
Northern Trust
24
Northern Trust
Illinois
$998K +$667K +41,857 New
Bank of New York Mellon
25
Bank of New York Mellon
New York
$846K +$565K +35,486 New
1
2 3

STML Hedge Fund Activity: Q2 2013 in Review

56 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q2 2013, worth a combined $184M.

Buyers outnumbered sellers: 56 funds opened new STML positions and 0 closed out — a net gain of 56 holders — while 0 added to existing stakes and 0 trimmed.

  • 56 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $184M of Stemline Therapeutics, Inc. stock for Q2 2013.
  • 56 funds opened new Stemline Therapeutics, Inc. positions in Q2 2013 and 0 closed out, a net change of +56 holders.

Based on aggregated 13F filings for Q2 2013.